i was wrong!, page-17

re: 20c to 91c and ? valuations are a guide only. They rely on the company delivering what they said they would. These valuations can be out if timing issues get in the way or if management dump truck loads of stock on the market like they did in ESI.There could be dozens of other reasons as well. So far so good with SLT and the punters need to be a bit patient at times or sell out.
These guys are deep in the deal making phase since 2 of the Hep style kits are ready for market. Most biotechs are simply blue sky and will never earn a cent. SLT is due its first revenues within the next 2 mths and more revenues when it does its HepA deal [ 5x the size]. They have based their valuation on a royalty rate and number of kits sold and these figures were based on the size of the market and number of cases etc.